Sentences with phrase «new lung cancer patients»

The drug had $ 942 million in global 2015 sales (versus $ 566 million for Keytruda) and, according to the company, has been prescribed to 60 % of new lung cancer patients.

Not exact matches

Related Articles: Merck's Keytruda held back by docs who don't want to wait for diagnostics Bristol's Opdivo - Yervoy combo ups response rates in first - line lung cancer patients Roche's Tecentriq bursts onto immuno - oncology scene, with Merck and BMS in its sights Bristol - Myers» new Opdivo ad touts biomarker advantage over Merck's Keytruda Merck's Keytruda lines up its survival data for stepped - up battle with BMS» Opdivo

The PD - 1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small cell lung cancer patients, beating chemo at staving off cancer progression and extending patients» lives.

Meanwhile, Bristol - Myers rolled out data from a new analysis comparing Opdivo and its fellow BMS immunotherapy Yervoy against Opdivo alone in previously untreated lung cancer patients.

For the new trial, hospitals enrolled patients with advanced, squamous non-small cell lung cancer whose disease had progressed despite initial chemotherapy.

«We urgently need new treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.

«Our findings suggest that this new drug combination would also help patients with this type of aggressive breast cancer as well as other cancers, such as lung, prostate and ovarian cancers,» Dr. Rassool says.

A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol - lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

UT Southwestern Medical Center researchers are developing a new predictive tool that could help patients with breast cancer and certain lung cancers decide whether follow - up treatments are likely to help.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

For the study, Gabriella Hobbs, MD, and Nancy Keating, MD, MPH, of Harvard Medical School, and their colleagues surveyed 5284 patients with a new diagnosis of lung or colon cancer, and asked participants how they involved their families in decisions about their care.

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicinew option for first line treatment of patients with advanced lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of MediciNew England Journal of Medicine.

An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

Research from McMaster University has identified new regulators of brain metastases in patients with lung cancer.

In one of the new papers, Zitvogel's group examined data for 249 lung, kidney, and bladder cancer patients, 69 of whom took antibiotics for routine reasons such as dental work or a urinary tract infection before or soon after starting a PD - 1 drug.

Thirty - seven percent of 154 lung cancer surgery patients in a new study were smoking again within a year.

There were 1,351 patients with a new diagnosis of primary lung cancer between 1984 and 2011.

«Rapid advancements in genetic testing offer new treatment options for patients with advanced lung cancer.

A new drug that targets not only common cancer - causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I / II clinical trial.

A lung cancer diagnosis appears to put patients at the greatest risk of suicide when compared to the most common types of non-skin cancers, according to new research presented at the ATS 2017 International Conference.

In a study of 124 patients with advanced breast, lung, and prostate cancers, a new, high - intensity genomic sequencing approach detected circulating tumor DNA at a high rate.

A new study shows that variations in the genes of Japanese and American lung cancer patients may contribute to how well their disease responds to chemotherapy

«More and more patients are being cured of lung cancer, with both surgery and radiation as good treatment options,» said lead author Nirav S. Kapadia, MD, of Dartmouth - Hitchcock Medical Center in New Hampshire.

Through CRI's Clinical Accelerator program, two new checkpoint inhibitor drugs, MEDI4736 (anti-PD-L1) and tremelimumab (anti-CTLA-4), are being tested in a phase I trial for patients with six different cancer types, including colorectal cancer, cervical cancer, head and neck cancer, kidney cancer, lung cancer, and ovarian cancer.

$ 1.8 M Supports Cancer Drug Discovery on Commonly Mutated Gene New Brunswick Patch — April 5, 2016 Behavioral Scientist Shares Insights about FDA's Proposed Rule on Banning Tanning Bed Use among Minors News-Medical.net - March 19, 2016 Intervention Program Reduces Caregiver Distress during Hospitalization of Pediatric Stem Cell Transplant Patients News-Medical.net - March 9, 2016 Exploring Genomic Pathways in the Development of Ovarian Cancer GMNews.com - March 2, 2016 Differences in Type of Small Protein may further Elucidate Lung Cancer Risk in African Americans ScienceDaily.com - March 2, 2016 Study Looks at Post-Treatment Resources for Prostate Cancer Patients Transitioning to Survivorship News-Medical.net - February 11, 2016 Drawing the Line on Tanning Bed Use by Teens ScienceDaily.com - December 21, 2015 What Rutgers Study Uncovered about E-Cigarette Use NJBiz.com - December 9, 2015 Identification of Barrier that Prevents Progression of Benign Kidney Tumors to Malignant Disease MedicalNewsToday.com - November, 24, 2015 What is the Color of the Lung Cancer Ribbon?

In the new study published in JAMA Oncology on June 4, Saad Khan, from the University of Texas Southwestern Medical Center, and colleagues said that a chunk of lung cancer patients with autoimmune disease are not eligible to receive the latest immunotherapy treatments.

The new database, which informs the Eighth Edition of the TNM Classification of Lung Cancer, consists of 94,708 patients diagnosed around the world from 1999 - 2010.

Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.

April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.

We're discovering new genetic alterations driving lung cancer, new drugs to target these alterations, and are refining our use of tests to find these alterations in individual patients,» says Dara Aisner, MD, PhD, investigator at the University of Colorado Cancer Center, molecular pathologist at CU School of Medicine Department of Pathology, and one of the panel excancer, new drugs to target these alterations, and are refining our use of tests to find these alterations in individual patients,» says Dara Aisner, MD, PhD, investigator at the University of Colorado Cancer Center, molecular pathologist at CU School of Medicine Department of Pathology, and one of the panel exCancer Center, molecular pathologist at CU School of Medicine Department of Pathology, and one of the panel experts.

City of Hope patients have access to a wide variety of clinical trials looking into early - detection for lung cancer, the newest chemotherapy treatments, targeted therapies and surgical and radiation approaches — all with the goal of helping extend life.

In this study, the new computer program and two other methods (called Random Forest and Support Vector Machine) were tested with blood samples from 29 liver cancer patients, 12 lung cancer patients and 5 breast cancer patients.

A new treatment, developed by Kimmel Cancer Center researchers, delivers radioactive «seeds» into the airways, extending life for inoperable lung cancer patCancer Center researchers, delivers radioactive «seeds» into the airways, extending life for inoperable lung cancer patcancer patients.

New immunotherapy drugs turned the gray hair of some lung cancer patients into black or dark brown.

Together, this work will further our understanding of lung cancer biology and create insight toward the development of new approaches to diagnose and treat patients suffering from this disease.